Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

PaperCitations, authors & open-access status

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 502 citations, 2020 year and bronze oa status.

502
Citations
2020
Year
bronze
OA Status

Related on ScholarIQ

Osamu Ogawa
Author
The Lancet Oncology
Journal
Bladder and Urothelial Cancer Treatments
Topic
Bladder and Urothelial Cancer Treatments
Topic
Cancer Immunotherapy and Biomarkers
Topic
Esophageal Cancer Research and Treatment
Topic
470M+ articles · free account